The know error® system utilizes bar coding, forensic principles and DNA Specimen Provenance Assay (DSPA) testing to confirm that surgical biopsy samples being evaluated belong exclusively to the patient being diagnosed and further confirm tissue specimens are free from contamination which can otherwise confound Biomarker Test results.
UroSeq™ is prognostic repair gene sequencing for prostate cancer patients (including BRCA). The testing is performed on the patient’s germline DNA. Strand uses buccal swabs already collected with the know error®system to obtain germline DNA samples sufficient to run its UroSeq™ Prostate Gene Panel test (BRCA1, BRCA2, ATM, CHEK2, PALB2 and RAD51D) in accordance with NCCN guidelines.
Your Biopsy Specimen. Your DNA. Your Diagnosis.
Know Error’s Patient Kit information lets you know if the Know Error DNA test is right for you. To oder start by calling for the free DNA swab kit, it’s simple, painless and delivered directly to you or your loved one.
Be DNA Certain™
By applying the same forensic principles used in law enforcement and criminal investigation to compare and match DNA profiles. Strand Diagnostics’ DSPA test (or DNA match) uses a buccal swab-to-biopsy tissue comparison to rule out the possibility of cancer misdiagnosis due to specimen contamination errors and confirms the cancer diagnosis is ascribed to the correct patient.
The patented know error system is increasingly becoming the standard of care for healthcare centers throughout the U.S. and can easily be integrated within any medical practice, surgery center, hospital facility, and/or pathology lab to deliver enhanced patient safety and diagnostic accuracy to the biopsy process.
Documented studies confirm that occult Specimen Provenance Complications (SPCs) happen at a rate of up to 3.5% which can result in a cancer diagnosis being assigned to the wrong patient; or in the case of Biomarker Testing admixtures (a specimen containing another’s DNA) can confound the test results and lead to incorrect conclusions and therapy. Further study analysis documents the societal economic burden of healthcare expenditures associated with undetected SPCs to exceed $880 million annually.
Rule out specimen contamination and patient misidentification errors before diagnosis and treatment with the know error system, the only solution to mitigate the clinical and economic impact of specimen provenance complications among surgical biopsies.